Authors
-
Karina Karina
Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia
-
Imam Rosadi
Department of Biology, Faculty of Mathematics and Natural Sciences, Mulawarman University, Samarinda, Indonesia
-
Grady Krisandi
Faculty of Medicine, University of Indonesia, Jakarta, Indonesia
-
Tommy P. Sibuea
Faculty of Medicine, Christian University of Indonesia, Jakarta, Indonesia
-
Johannes Albert Biben
Hayandra Clinic, Hayandra Peduli Foundation, Jakarta, Indonesia
-
Krista Ekaputri
Hayandra Clinic, Hayandra Peduli Foundation, Jakarta, Indonesia
-
Diani Nazma
Faculty of Medicine, Trisakti University, Jakarta, Indonesia
-
Azza Maryam
Hayandra Clinic, Hayandra Peduli Foundation, Jakarta, Indonesia
-
Siti Sobariah
HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia
-
Elisa Christina Jaman
Hayandra Clinic, Hayandra Peduli Foundation, Jakarta, Indonesia
-
Cecilia Sagita Wibisana
Hayandra Clinic, Hayandra Peduli Foundation, Jakarta, Indonesia
-
Jessica Miranda
Hayandra Clinic, Hayandra Peduli Foundation, Jakarta, Indonesia
-
Irsyah Afini
HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia
-
Difky Ernanda
HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia
-
Tias Widyastuti
HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia
-
Alfida Zakiyah
HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia
-
Noor Aini
HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia
Keywords:
coronavirus disease 2019, nephrotic syndrome, platelet-rich plasma, stromal vascular fraction
Abstract
Extrapulmonary complications in currently infected or recovered COVID-19 patients is a concerning problem. One of these complications is post-COVID nephrotic syndrome which usually requires anti-inflammatory agent for treatment. Among the various anti-inflammatory agents available, the combination of autologous activated platelet-rich plasma (aaPRP) and stromal vascular fraction (SVF) is a potential breakthrough therapy. It not only exerts an anti-inflammatory effect, but also a regenerative effect. To our knowledge, this is the first report of aaPRP and SVF therapy in post-COVID nephrotic syndrome patient. A 27-year-old type 1 diabetic female patient was admitted to Hayandra Clinic with symptoms of nephrotic syndrome after being recovered from COVID-19. The use of SVF and aaPRP combination therapy showed immediate significant improvement in patient’s overall kidney function and clinical manifestations.